Biotech · Public company · Boston, MA, US

Zevra Therapeutics, Inc.

Ticker ZVRA · SEC CIK 0001434647

Track this companyFree. Adds Zevra Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials52 recruiting or active

Pipeline programs2From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline2

KP415 oral capsulePhase 3 · ADHDClinicalTrials.gov · fetched Nov 12, 2026
SerdexmethylphenidatePhase 2 · Idiopathic HypersomniaClinicalTrials.gov · fetched Nov 12, 2026

An Individual Patient, Open Label Study to Use ACER-001 to Treat Combined D,L-2 Hydroxyglutaric Aciduria (C-2HGA)PHASE1 · ENROLLING_BY_INVITATION · started Jul 30, 2025ClinicalTrials.gov NCT07125066 · fetched Nov 12, 2026
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)PHASE2 · RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT06773026 · fetched Nov 12, 2026
Study of SDX in Patients With Idiopathic Hypersomnia (IH)PHASE2 · COMPLETED · started Dec 28, 2022ClinicalTrials.gov NCT05668754 · fetched Nov 12, 2026
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHDPHASE3 · COMPLETED · started Mar 13, 2018ClinicalTrials.gov NCT03460652 · fetched Nov 12, 2026
KP415 Classroom Study in Children (6-12 Years of Age) With ADHDPHASE3 · COMPLETED · started Dec 20, 2017ClinicalTrials.gov NCT03292952 · fetched Nov 12, 2026